Bladder Cancer

As leaders in the development of the most sophisticated treatments for people with bladder cancer, we have one of the largest bladder cancer clinical trials program in the United States. Our doctors are leading innovative clinical trials to treat noninvasive bladder cancer—the most common type. Our team of urologic surgeons, medical oncologists, radiation oncologists, imaging specialists, and urologic pathologists collaborates to diagnose and treat people who have bladder cancer.

Our research studies give you access to the newest approaches to care, including the latest diagnostic imaging techniques, such as PET/MRI scans, and advanced treatments, including immunotherapy, and blue light cystoscopy to detect and remove early stage bladder cancer. We are also at the forefront of surgical treatment of bladder cancer, including robotic-assisted surgery, bladder reconstructive surgery, and nerve-sparing techniques that help preserve urinary and sexual function.

Clinical Trials and Research Studies

Phase 3

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer

Learn More

Phase 3

A Phase 3 Randomized Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1 and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

Learn More

Phase 3

A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)

Learn More

Phase 1

A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas

Learn More